Lopez-Bujanda, Zoila A.
Haffner, Michael C.
Chaimowitz, Matthew G.
Chowdhury, Nivedita http://orcid.org/0000-0001-7327-3067
Venturini, Nicholas J. http://orcid.org/0000-0002-3769-5956
Patel, Radhika A.
Obradovic, Aleksandar
Hansen, Corey S.
Jacków, Joanna
Maynard, Janielle P.
Sfanos, Karen S. http://orcid.org/0000-0002-7015-3059
Abate-Shen, Cory
Bieberich, Charles J.
Hurley, Paula J.
Selby, Mark J.
Korman, Alan J.
Christiano, Angela M.
De Marzo, Angelo M.
Drake, Charles G. http://orcid.org/0000-0001-9610-3677
Article History
Received: 26 November 2020
Accepted: 26 May 2021
First Online: 19 July 2021
Competing interests
: C.G.D. has served as a consultant for Agenus, Dendreon, Janssen Oncology, Eli Lilly, Merck, AstraZeneca, MedImmune, Pierre Fabre, Genentech and Genocea Biosciences. A.M.C. is a shareholder of Aclaris Therapeutics and a consultant for Dermira and Aclaris Therapeutics. Columbia University has filed a US patent claiming the benefit of US provisional patent application number 62/809,060 (inventors C.G.D. and Z.A.L.-B.) on the use of IL-8/CXCR2 blockade of PMN-MDSC recruitment to the TME for the treatment of prostate cancer. The remaining authors declare no competing interests.